

|                                                       |                                               |                                         |                 |                  |
|-------------------------------------------------------|-----------------------------------------------|-----------------------------------------|-----------------|------------------|
| Patient ID<br><b>321</b>                              | Patient Name<br><b>TESTRNV, TESTING ATLAS</b> | Birth Date<br><b>1968-02-19</b>         | Sex<br><b>M</b> | Age<br><b>55</b> |
| Order Number<br><b>X100427946</b>                     | Client Order Number<br><b>X100427946</b>      | Ordering Physician<br><b>Test,Atlas</b> | Report Notes    |                  |
| Account Information<br><b>C7028846 DLMP Rochester</b> |                                               | Collected<br><b>30 Aug 2023 06:33</b>   |                 |                  |

## G6PD Full Gene Sequencing, V

### G6PD Phenotype

MCR

G6PD deficiency

### Result Details

MCR

The following variant was detected in G6PD (NM\_001042351.2):

**Variant Name:** A- (202), Ferrara I

**Zygosity:** hemizygous

**gDNA change :** ChrX(GRCh37):g.[153764217;153763492]

**cDNA change:** c.[202G>A;376A>G]

**Amino Acid change:** p.[Val68Met;Asn126Asp]

WHO Class: B

### Interpretation

MCR

The c.[202G>A;376A>G] (p.[Val68Met;Asn126Asp]) variant in the G6PD gene is a WHO Class B variant. The presence of this variant in the hemizygous state is supportive of a diagnosis of G6PD deficiency.

Caution should be exercised when treating with drugs associated with a risk of hemolysis in G6PD-deficient individuals. Some drugs may be contraindicated.

Clinical correlation is recommended. A genetic consultation may be of benefit. This report uses the revised WHO classification system (2022). See Additional Information below for guidance on converting revised WHO classification to legacy classification.

### Additional Information

MCR

The following is based on the publication entitled "Technical consultation to review the classification of glucose-6-phosphate dehydrogenase (G6PD), 25 and 27 January 2022, virtual meeting":

Updated WHO Classification of G6PD Variants in Homozygous And Hemizygous Individuals (2022) Note: This system is used for classifying genetic variants, not individual patients

| Class | Median G6PD Activity | Hemolysis              |
|-------|----------------------|------------------------|
| A     | <20%                 | Chronic (CNSHA)        |
| B     | <45%                 | Acute, triggered       |
| C     | 60–150%              | No hemolysis           |
| U     | Any                  | Uncertain significance |

Global Malaria Programme, Malaria Policy Advisory Group. (2022). Meeting report of the technical consultation to review the classification of glucose-6-phosphate dehydrogenase (G6PD). WHO Reference Number: WHO/UCN/GMP/MPAG/2022.01. Available at [www.who.int/publications/m/item/WHO-UCN-GMP-MPAG-2022.01](http://www.who.int/publications/m/item/WHO-UCN-GMP-MPAG-2022.01) Accessed July 29, 2022.

### Legacy WHO Classification

| G6PD Classification | Residual Enzyme Activity (% normal) |
|---------------------|-------------------------------------|
| Class I             | <10% with CNSHA                     |
| Class II            | <10%                                |
| Class III           | 10–60%                              |
| Class IV            | 60%-150%                            |
| Class V             | More than twice normal              |

### Method

MCR

Bidirectional fluorescent DNA sequence analysis was used to test for the presence of variants in the G6PD gene (transcript NM\_001042351.2; build GRCh37 (hg19)) for all exons and intron-exon boundaries.

### Performing Site Legend

| Code | Laboratory                                       | Address                                  | Lab Director                | CLIA Certificate |
|------|--------------------------------------------------|------------------------------------------|-----------------------------|------------------|
| MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292       |

|                                                       |                                               |                                         |                 |                  |
|-------------------------------------------------------|-----------------------------------------------|-----------------------------------------|-----------------|------------------|
| Patient ID<br><b>321</b>                              | Patient Name<br><b>TESTRNV, TESTING ATLAS</b> | Birth Date<br><b>1968-02-19</b>         | Sex<br><b>M</b> | Age<br><b>55</b> |
| Order Number<br><b>X100427946</b>                     | Client Order Number<br><b>X100427946</b>      | Ordering Physician<br><b>Test,Atlas</b> | Report Notes    |                  |
| Account Information<br><b>C7028846 DLMP Rochester</b> |                                               | Collected<br><b>30 Aug 2023 06:33</b>   |                 |                  |

**Disclaimer**
**1 MCR**

Evaluation and categorization of variants is performed using available literature and variant classification guidelines. At this time, it is not standard practice for the laboratory to systematically re-review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time. Consultation with genetics professional should be considered for interpretation of this result.

A list of benign and likely benign variants identified for this patient is available from the laboratory upon request.

Multiple in silico evaluation tools may be used to assist in the interpretation of these results and predictions made by these tools may change over time.

Patients with negative G6PD sequencing results may still experience hemolysis either due to genetic variation that is not identified by the methods utilized here or due to other factors.

**CAUTIONS :**

Rare variants may be present that could impact results. This assay may not detect large deletions or rearrangements that may affect G6PD protein expression. If more than one heterozygous variant is detected, the cis/trans relationship (i.e. whether the variants are inherited on the same or opposite alleles) of these variants typically cannot be definitively determined with the methods used by this assay. In addition, the reported zygosity of variants is based on reported patient sex. Note, due to skewed X-chromosome inactivation, elderly heterozygous carriers may be at increased risk of G6PD deficiency. Therefore, test results should be interpreted in the context of clinical findings, family

history, and other laboratory data. Samples may contain donor DNA if obtained from patients who received non-leukocyte reduced blood transfusions or allogeneic hematopoietic stem cell transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient's genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic hematopoietic stem cell transplantation, a pretransplant DNA specimen is recommended for testing.

For a list of drugs associated with increased risk for hemolysis in G6PD-deficient individuals see the Pharmacogenomics Association Tables on the Mayo Clinic Laboratories webpage, [www.mayocliniclabs.com](http://www.mayocliniclabs.com) or the list available at the following page: [www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare\\_ISS-it](http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it) Please note that the information at these links is educational material intended for health care professionals and may not be comprehensive. This educational material is not intended to supersede the care provider's experience and knowledge of her/his patient to establish a diagnosis or a treatment plan. All medications require careful clinical monitoring. If results do not correlate with this individual's clinical presentation, consider G6PD enzymatic studies or other laboratory testing. For information about G6PD enzymatic studies, please contact the laboratory at 1-800-533-1710 or the online test catalog at [www.mayocliniclabs.com](http://www.mayocliniclabs.com) about the test G6PD Enzyme Activity, B (test code G6PD1).

**Reviewed By**
**MCR**

Ann Marie Moyer, M.D., Ph.D.

**Received:** 30 Aug 2023 13:20

**Reported:** 07 Sep 2023 17:07

**Laboratory Notes**

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**Performing Site Legend**

| Code | Laboratory                                       | Address                                  | Lab Director                | CLIA Certificate |
|------|--------------------------------------------------|------------------------------------------|-----------------------------|------------------|
| MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292       |